SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : NBMX - National Boston Medical (was FGRX)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: sean who wrote (1100)3/4/1999 11:41:00 AM
From: William Hayden  Read Replies (2) of 1286
 
NBMX News!!!

(COMTEX) B: NBM REPORTS $630,000 INITIAL SALE OF SAFESHIELD(TM) THROU
B: NBM REPORTS $630,000 INITIAL SALE OF SAFESHIELD(TM) THROUGH

New Master Distributor, DermaGuard, Inc.

TAUNTON, Mass., March 4 /PRNewswire/ -- National Boston Medical (OTC
Bulletin Board: NBMX) (NBM) has signed Dermaguard, Inc. of New Orleans,
Louisiana, as a Master Distributor for its proprietary SafeShield(TM)
anti-microbial barrier lotion.

Dermaguard has developed a number of brokers and distributors for
SafeShield(TM) in the food service, medical and retail markets, and has
placed an initial order for $630,000.

"SafeShield has many applications beyond the important use in medical
practice," said Dermaguard CEO Alvarez Ferrouillet. "We are excited to
work with National Boston Medical to introduce this unique product to a
number of markets. These include retail and food service, where there
is an increasing awareness of hand-transmitted viruses and bacteria,
and clear demand for a durable and highly-effective product like
SafeShield."

Dermaguard plans to secure more than 70 product brokers for SafeShield
and $6 million in sales before the end of the year. As part of its
distribution agreement, NBM acquired a 5% ownership in Dermaguard in
exchange for 150,000 shares of NBM's common stock.

SafeShield is a topical polymeric barrier that can eliminate the need
for latex gloves or frequent hand washings. This revolutionary product
helps prevent the spread of infectious disease and exposure to
hazardous agents through a unique and proprietary, anti-microbial
barrier lotion that maintains integrity for three or more hours, even
after repeated hand washing.

SafeShield is designed for businesses or consumers that are concerned
with cross contamination of infectious diseases; damaged skin from
latex gloves or frequent hand washing; foodborne illness due to
contaminated food handlers; as well as those simply desiring healthy
and beautiful hands.

National Boston Medical is a developer and marketer of quality
healthcare products. It is the exclusive provider of Bontempi medical
instruments in North America and on the Internet. NBM is the developer
of SafeShield(TM), a topical polymeric barrier that can replace the
need for latex gloves or frequent hand washings. NBM also markets
Vertason and VertaVac, environmentally-friendly enzymatic cleaning
solutions for use in the dental industry. It recently acquired Flex
Marketing, Inc., which offers consumer products to the healthcare,
fitness, and recreation markets, including the popular Backstroke(R)
back massager. NBM's Medical Advisory Board is comprised of twenty-five
award-winning medical professionals.

For further information, please visit the company's web site at:
nbmedical.com.

Company contacts: Daniel J. Hoyng, president of NBM, 800-807-2259;
Alvarez Ferrouillet, CEO of DermaGuard 504-269-0068; Len Harris or
James Dryer, investor relations, 561-655-7575, fax 561-655-2171,
e-mail: jamesdryer@aol.com.

This press release may contain forward-looking statements, which may be
affected by a variety of factors, many of which are beyond the control
of the company. These factors include the levels of orders that are
received and can be shipped in a quarter; customer order patterns and
seasonability; contract mix and shifting production and delivery
schedules; manufacturing capacity and yield; cost of labor, raw
materials, supplies and equipment; technological changes; competition
and competitive pressures on pricing; economic conditions, as well as
other risks and uncertainties that are detailed from time to time in
the company's filings with the Securities and Exchange Commission.
SOURCE National Boston Medical

-0- 03/04/99 /CONTACT: Daniel J. Hoyng,
president of National Boston Medical, 800-807-2259; or Alvarez
Ferrouillet, CEO of Dermaguard, 504-269-0068; or James Dryer or
Geoffrey Plank, public & investor relations, 561-655-7575/

/Web site: nbmedical.com (NBMX)
CO: National Boston Medical; Dermaguard, Inc. ST: Massachusetts,
Louisiana IN: HEA SU: PDT

*** end of story ***
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext